TH MEDICAL-B Surges Over 23% in Early Trading as Leader in Percutaneous Puncture Surgical Robots

Deep News07-13 11:21

Shares of TH MEDICAL-B (02697) surged more than 23% during the morning session. As of the time of writing, the stock is up 22.38%, trading at HK$445.20 with a turnover of HK$18.82 million.

Public information shows the company's core products are percutaneous puncture surgical robots, with four models (THS1, TH-S, TH-SPro, and TH-SA). All have obtained Class III registration certificates from the National Medical Products Administration and are approved for use in lung and abdominal punctures. Concurrently, the company is expanding the indications for its TH-S1 model to include retroperitoneal lesions. According to data from a consulting firm, based on projected revenue for percutaneous puncture surgical robots in 2025, the company ranks first in China with a market share of 28.0%.

It is noteworthy that in early 2026, the National Healthcare Security Administration's pricing framework for surgical robots was implemented. Provinces including Hunan, Guangdong, and Guizhou have followed up by introducing pricing for puncture surgical robot medical services, clearing policy obstacles. Coupled with the expected attainment of CE certification in the fourth quarter, significant volume growth in 2026 is anticipated.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182751202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 11:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182751202","market":"hk","top_or_hot":-1,"title":"TH MEDICAL-B Surges Over 23% in Early Trading as Leader in Percutaneous Puncture Surgical Robots","media":"Deep News","content":"<p>Shares of <b>TH MEDICAL-B</b> (<b>02697</b>) surged more than 23% during the morning session. As of the time of writing, the stock is up 22.38%, trading at HK$445.20 with a turnover of HK$18.82 million.<br><br>\nPublic information shows the company's core products are percutaneous puncture surgical robots, with four models (THS1, TH-S, TH-SPro, and TH-SA). All have obtained Class III registration certificates from the National Medical Products Administration and are approved for use in lung and abdominal punctures. Concurrently, the company is expanding the indications for its TH-S1 model to include retroperitoneal lesions. According to data from a consulting firm, based on projected revenue for percutaneous puncture surgical robots in 2025, the company ranks first in China with a market share of 28.0%.<br><br>\nIt is noteworthy that in early 2026, the National Healthcare Security Administration's pricing framework for surgical robots was implemented. Provinces including Hunan, Guangdong, and Guizhou have followed up by introducing pricing for puncture surgical robot medical services, clearing policy obstacles. Coupled with the expected attainment of CE certification in the fourth quarter, significant volume growth in 2026 is anticipated.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TH MEDICAL-B Surges Over 23% in Early Trading as Leader in Percutaneous Puncture Surgical Robots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTH MEDICAL-B Surges Over 23% in Early Trading as Leader in Percutaneous Puncture Surgical Robots\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-13 11:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>TH MEDICAL-B</b> (<b>02697</b>) surged more than 23% during the morning session. As of the time of writing, the stock is up 22.38%, trading at HK$445.20 with a turnover of HK$18.82 million.<br><br>\nPublic information shows the company's core products are percutaneous puncture surgical robots, with four models (THS1, TH-S, TH-SPro, and TH-SA). All have obtained Class III registration certificates from the National Medical Products Administration and are approved for use in lung and abdominal punctures. Concurrently, the company is expanding the indications for its TH-S1 model to include retroperitoneal lesions. According to data from a consulting firm, based on projected revenue for percutaneous puncture surgical robots in 2025, the company ranks first in China with a market share of 28.0%.<br><br>\nIt is noteworthy that in early 2026, the National Healthcare Security Administration's pricing framework for surgical robots was implemented. Provinces including Hunan, Guangdong, and Guizhou have followed up by introducing pricing for puncture surgical robot medical services, clearing policy obstacles. Coupled with the expected attainment of CE certification in the fourth quarter, significant volume growth in 2026 is anticipated.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HTEC","symbol_name":"ROBO Global Healthcare Technology and Innovation ETF","start_time":0,"source_url":"","article_id":"1182751202","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182751202","pubTimestamp":1783912882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of TH MEDICAL-B (02697) surged more than 23% during the morning session. As of the time of writing, the stock is up 22.38%, trading at HK$445.20 with a turnover of HK$18.82 million. Public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","HTEC":"ROBO Global Healthcare Technology and Innovation ETF","02697":"真健康医疗-B","MDEV":"First Trust Indxx Medical Devices ETF"},"translate_title":"TH MEDICAL-B 成为经皮穿刺手术机器人领导者，早盘交易中股价飙升超过 23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"02697":1,"HTEC":1,"MDEV":1},"content_text":"Shares of TH MEDICAL-B (02697) surged more than 23% during the morning session. As of the time of writing, the stock is up 22.38%, trading at HK$445.20 with a turnover of HK$18.82 million.\nPublic information shows the company's core products are percutaneous puncture surgical robots, with four models (THS1, TH-S, TH-SPro, and TH-SA). All have obtained Class III registration certificates from the National Medical Products Administration and are approved for use in lung and abdominal punctures. Concurrently, the company is expanding the indications for its TH-S1 model to include retroperitoneal lesions. According to data from a consulting firm, based on projected revenue for percutaneous puncture surgical robots in 2025, the company ranks first in China with a market share of 28.0%.\nIt is noteworthy that in early 2026, the National Healthcare Security Administration's pricing framework for surgical robots was implemented. Provinces including Hunan, Guangdong, and Guizhou have followed up by introducing pricing for puncture surgical robot medical services, clearing policy obstacles. Coupled with the expected attainment of CE certification in the fourth quarter, significant volume growth in 2026 is anticipated.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182751202","isCrawlerRequest":true}